Danaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024.
- Revenue
- +8.28%
- EPS
- +36.7%
- Free cash flow
- +19.1%
- Total debt
- +44.9%
Quarter to September 2026, against a year earlier
Follow DHR
Alert me
Danaher Corporation (DHR) valuation and DCF model
At $227.87 the price implies free cash flow after share-based pay growing 12.4% a year for ten years.
Free cash flow after share-based pay grew 5.7% a year over the last ten years, −4.8% over the last five. The price asks for about twice its ten-year rate. The industry’s median company is priced for 15.8%.
In December 2017 the price assumed 9.3% a year; Danaher Corporation went on to grow free cash flow after share-based pay 7.4% a year to FY2025.
- The price needs
- 12.4% a year for ten years
- $227.87
- today’s price
- Its base case
- 5.7% a year for five years, then 3.4%
- $116.29
- 49.0% below today’s price
Base case on its own ten-year record Danaher Corporation’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$44.75b 10 years of cash to equity+$56.58b terminal value−$18.71b net debt=$82.62b equity value÷710.43m shares=$116.29 per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/E | 36.97× | 37.05× | 33.77× | 9% above | 34.52× | 7% above | |
| P/FCF | 27.69× | 28.53× | 26.42× | 5% above | 33.51× | 17% below | |
| P/B | 2.97× | 3.23× | 3.27× | 9% below | 3.42× | 13% below | |
| EV/EBITDA | 22.31× | 23.15× | 22.35× | 0% below | 23.44× | 5% below | |
| EV/Sales | 6.95× | 7.25× | 6.63× | 5% above | 5.18× | 34% above |
DHR trades at 36.97× P/E, against a 10-year average of 33.77× (range 22.80×–45.15×). That is dearer than 67% of the last 9 year-end readings; re-rating to the average implies $208.15 per share.